Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis, Abbott to Develop CDx Tests for Idylla Platform

NEW YORK (GenomeWeb) – Molecular diagnostics firm Biocartis and Abbott today announced a collaboration to develop and commercialize companion diagnostic tests for use on Biocartis' Idylla system.

Under the terms of the deal, the firms will leverage Biocartis' and Abbott's regulatory, scientific, and commercialization expertise, and in partnership with pharmaceutical companies, they will create biomarker panels for use on Idylla where each biomarker in the panel has known clinical significance.

Idylla is a fully automated sample-in, result-out molecular diagnostics platform and is Biocartis' flagship instrument for in vitro diagnostic use. The company, which has offices in Belgium and Switzerland, has said that it plans to launch Idylla along with a test for BRAF mutations in melanoma and other cancers in Europe in the second half of 2014. Late last year Biocartis raised €30 million ($40.6 million) for the validation of the platform and the development of assays.

Financial terms of today's deal were not disclosed.

In addition to Idylla, Biocartis is developing a multiplex platform for biomarker analysis called Evaluation, and recently announced an agreement with Invetech to support its development and manufacture.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.